Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.

Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases. ##STR00001##

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases. ##STR00001##

The present invention generally relates to electrochromic compounds and the uses thereof, particularly to series of fluoroalkyl 3,4-dioxythiophene compounds and their electrochromic polymers or co-polymers. Both compositions and process for manufacturing thereof are in the scope of this invention.

The present invention generally relates to electrochromic compounds and the uses thereof, particularly to series of fluoroalkyl 3,4-dioxythiophene compounds and their electrochromic polymers or co-polymers. Both compositions and process for manufacturing thereof are in the scope of this invention.

Disclosed herein are embodiments of polycyclic aromatic compounds and methods of making and using the same. Various different types of polycyclic ring systems are disclosed, including, but not limited to, polymeric aromatic compounds (e.g., nanographene compounds), pentacene-like compounds, chiral aromatic compounds, asymmetric arene compounds formed from naphthalene-, anthracene-, phenanthrene-, and pyrene-based starting compounds, and dimerized aromatic compounds. Also disclosed herein are novel benzannulation-based methods for making the disclosed polycyclic aromatic compounds.

Disclosed herein are embodiments of polycyclic aromatic compounds and methods of making and using the same. Various different types of polycyclic ring systems are disclosed, including, but not limited to, polymeric aromatic compounds (e.g., nanographene compounds), pentacene-like compounds, chiral aromatic compounds, asymmetric arene compounds formed from naphthalene-, anthracene-, phenanthrene-, and pyrene-based starting compounds, and dimerized aromatic compounds. Also disclosed herein are novel benzannulation-based methods for making the disclosed polycyclic aromatic compounds.

The invention provides a compound of formula (I): ##STR00001##
or a salt thereof, wherein R.sup.1 and R.sup.2 have any of the values defined in the specification, as well as methods of using such compounds and salts to separate an aryl compound from a mixture.

The invention provides a compound of formula (I): ##STR00001##
or a salt thereof, wherein R.sup.1 and R.sup.2 have any of the values defined in the specification, as well as methods of using such compounds and salts to separate an aryl compound from a mixture.